Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)-Reference-Cited by-同舟云学术

Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)

Published:2019-05 Issue: Volume:112 Page:66-79
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Pinto Navin^ORCID,Naranjo Arlene,Hibbitts Emily^ORCID,Kreissman Susan G.,Granger M. Meaghan,Irwin Meredith S.,Bagatell Rochelle,London Wendy B.,Greengard Emily G.,Park Julie R.,DuBois Steven G.

Funder

National Institutes of Health

NCTN Operations Center

St. Baldrick's Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Advances in risk classification and treatment strategies for neuroblastoma;Pinto;J Clin Oncol,2015

2. The international neuroblastoma risk group (INRG) classification system: an INRG task force report;Cohn;J Clin Oncol,2009

3. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party;Philip;Eur J Cancer,1997

4. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study;Matthay;J Clin Oncol,2009

5. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial;Kreissman;Lancet Oncol,2013

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A subset of image‐defined risk factors predict completeness of resection in children with high‐risk neuroblastoma: An international multicenter study;Pediatric Blood & Cancer;2024-07-28

2. Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531;Pediatric Blood & Cancer;2024-05-31

3. Distinct Expression Profiles of Neuroblastoma-Associated mRNAs in Peripheral Blood and Bone Marrow of Non-High-Risk and High-Risk Neuroblastoma Patients;Biology;2024-05-15

4. Updates in the Management of Neuroblastoma;Journal of the National Comprehensive Cancer Network;2024-05

5. Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy;Cancers;2024-04-29